Literature DB >> 28040566

Marked sexual dimorphism in 5-HT1 receptors mediating pronociceptive effects of sumatriptan.

Dioneia Araldi1, Luiz F Ferrari1, Paul Green2, Jon D Levine3.   

Abstract

Amongst the side effects of triptans, a substantial percentage of patients experience injection site pain and tenderness, the underlying mechanism of which is unknown. We found that the dose range from 10fg to 1000ng (intradermal) of sumatriptan induced a complex dose-dependent mechanical hyperalgesia in male rats, with distinct peaks, at 1pg and 10ng, but no hyperalgesia at 1ng. In contrast, in females, there was 1 broad peak. The highest dose (1000ng) did not produce hyperalgesia in either sex. We evaluated the receptors mediating sumatriptan hyperalgesia (1pg, 1 and 10ng). In males, the injection of an antagonist for the serotonin (5-HT) receptor subtype 1B (5-HT1B), but not 5-HT1D, markedly inhibited sumatriptan (1pg)-induced hyperalgesia, at 10ng a 5-HT1D receptor antagonist completely eliminated hyperalgesia. In contrast, in females, the 5-HT1D, but not 5-HT1B, receptor antagonist completely blocked sumatriptan (1pg and 10ng) hyperalgesia and both 5-HT1B and 5-HT1D receptor antagonists attenuated hyperalgesia (1ng) in females, which is GPR30 estrogen receptor dependent. While selective 5-HT1D or 5-HT1B, agonists produce robust hyperalgesia in female and male rats, respectively, when co-injected the hyperalgesia induced in both sexes was attenuated. Mechanical hyperalgesia induced by sumatriptan (1pg and 10ng) is dependent on the G-protein αi subunit and protein kinase A (PKA), in IB4-positive and negative nociceptors. Understanding the mechanisms responsible for the complex dose dependence for triptan hyperalgesia may provide useful information for the design of anti-migraine drugs with improved therapeutic profiles.
Copyright © 2017 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  5-HT(1B) receptor; 5-HT(1D) receptor; hyperalgesia; migraine; triptans

Mesh:

Substances:

Year:  2016        PMID: 28040566      PMCID: PMC5321636          DOI: 10.1016/j.neuroscience.2016.12.031

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  70 in total

1.  The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain.

Authors:  Valérie Kayser; Bertrand Aubel; Michel Hamon; Sylvie Bourgoin
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Effects of isolectin B4-conjugated saporin, a targeting cytotoxin, on bladder overactivity induced by bladder irritation.

Authors:  Jun Nishiguchi; Katsumi Sasaki; Satoshi Seki; Michael B Chancellor; Kristin A Erickson; William C de Groat; Hiromi Kumon; Naoki Yoshimura
Journal:  Eur J Neurosci       Date:  2004-07       Impact factor: 3.386

3.  5-HT(1B) and 5-HT(1D) receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase.

Authors:  M Hou; M Kanje; J Longmore; J Tajti; R Uddman; L Edvinsson
Journal:  Brain Res       Date:  2001-08-03       Impact factor: 3.252

4.  Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX STATdose System.

Authors:  G R Mushet; R K Cady; C C Baker; B Clements; D L Gutterman; R Davis
Journal:  Clin Ther       Date:  1996 Jul-Aug       Impact factor: 3.393

5.  Plasma membrane mechanisms in a preclinical rat model of chronic pain.

Authors:  Luiz F Ferrari; Jon D Levine
Journal:  J Pain       Date:  2014-11-04       Impact factor: 5.820

6.  Altered quantitative sensory testing outcome in subjects with opioid therapy.

Authors:  Lucy Chen; Charlene Malarick; Lindsey Seefeld; Shuxing Wang; Mary Houghton; Jianren Mao
Journal:  Pain       Date:  2009-02-23       Impact factor: 6.961

7.  Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. The Subcutaneous Sumatriptan International Study Group.

Authors:  W H Visser; M D Ferrari; E M Bayliss; S Ludlow; A J Pilgrim
Journal:  Cephalalgia       Date:  1992-10       Impact factor: 6.292

Review 8.  Sumatriptan for the treatment of migraine attacks--a review of controlled clinical trials.

Authors:  P Tfelt-Hansen
Journal:  Cephalalgia       Date:  1993-08       Impact factor: 6.292

9.  Is chest pain after sumatriptan oesophageal in origin?

Authors:  L A Houghton; J M Foster; P J Whorwell; J Morris; P Fowler
Journal:  Lancet       Date:  1994-10-08       Impact factor: 79.321

10.  Role of nociceptor estrogen receptor GPR30 in a rat model of endometriosis pain.

Authors:  Pedro Alvarez; Oliver Bogen; Jon D Levine
Journal:  Pain       Date:  2014-10-02       Impact factor: 6.961

View more
  13 in total

1.  Role of Nociceptor Toll-like Receptor 4 (TLR4) in Opioid-Induced Hyperalgesia and Hyperalgesic Priming.

Authors:  Dioneia Araldi; Oliver Bogen; Paul G Green; Jon D Levine
Journal:  J Neurosci       Date:  2019-06-17       Impact factor: 6.167

Review 2.  Qualitative sex differences in pain processing: emerging evidence of a biased literature.

Authors:  Jeffrey S Mogil
Journal:  Nat Rev Neurosci       Date:  2020-05-21       Impact factor: 34.870

3.  Fentanyl Induces Rapid Onset Hyperalgesic Priming: Type I at Peripheral and Type II at Central Nociceptor Terminals.

Authors:  Dioneia Araldi; Eugen V Khomula; Luiz F Ferrari; Jon D Levine
Journal:  J Neurosci       Date:  2018-02-05       Impact factor: 6.167

4.  Opioid-Induced Hyperalgesic Priming in Single Nociceptors.

Authors:  Eugen V Khomula; Dionéia Araldi; Ivan J M Bonet; Jon D Levine
Journal:  J Neurosci       Date:  2020-11-17       Impact factor: 6.167

5.  Modulation of brain networks by sumatriptan-naproxen in the inflammatory soup migraine model.

Authors:  James Bishop; Lino Becerra; Gabi Barmettler; Pei-Ching Chang; Vanessa Kainz; Rami Burstein; David Borsook
Journal:  Pain       Date:  2019-09       Impact factor: 7.926

6.  Role of GPCR (mu-opioid)-receptor tyrosine kinase (epidermal growth factor) crosstalk in opioid-induced hyperalgesic priming (type II).

Authors:  Dionéia Araldi; Luiz F Ferrari; Jon D Levine
Journal:  Pain       Date:  2018-05       Impact factor: 7.926

7.  Sexual dimorphism in the nociceptive effects of hyaluronan.

Authors:  Ivan J M Bonet; Paul G Green; Jon D Levine
Journal:  Pain       Date:  2021-04-01       Impact factor: 7.926

Review 8.  Sex differences in pain along the neuraxis.

Authors:  Peyton Presto; Mariacristina Mazzitelli; Riley Junell; Zach Griffin; Volker Neugebauer
Journal:  Neuropharmacology       Date:  2022-03-21       Impact factor: 5.273

9.  Peripherally administered calcitonin gene-related peptide induces spontaneous pain in mice: implications for migraine.

Authors:  Brandon J Rea; Anne-Sophie Wattiez; Jayme S Waite; William C Castonguay; Chantel M Schmidt; Aaron M Fairbanks; Bennett R Robertson; Cameron J Brown; Bianca N Mason; Maria-Cristina Moldovan-Loomis; Leon F Garcia-Martinez; Pieter Poolman; Johannes Ledolter; Randy H Kardon; Levi P Sowers; Andrew F Russo
Journal:  Pain       Date:  2018-11       Impact factor: 7.926

10.  Repetitive stress in mice causes migraine-like behaviors and calcitonin gene-related peptide-dependent hyperalgesic priming to a migraine trigger.

Authors:  Amanda Avona; Bianca N Mason; Jacob Lackovic; Naureen Wajahat; Marina Motina; Lilyana Quigley; Carolina Burgos-Vega; Cristina Moldovan Loomis; Leon F Garcia-Martinez; Armen N Akopian; Theodore J Price; Gregory Dussor
Journal:  Pain       Date:  2020-11       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.